BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 19416474)

  • 1. The EGFR-GEP100-Arf6-AMAP1 signaling pathway specific to breast cancer invasion and metastasis.
    Sabe H; Hashimoto S; Morishige M; Ogawa E; Hashimoto A; Nam JM; Miura K; Yano H; Onodera Y
    Traffic; 2009 Aug; 10(8):982-93. PubMed ID: 19416474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model.
    Otsuka Y; Oikawa T; Yoshino H; Hashimoto S; Handa H; Yamamoto H; Hashimoto A; Sabe H
    Cell Commun Signal; 2018 Jan; 16(1):1. PubMed ID: 29329590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The EGFR-GEP100-Arf6 pathway in breast cancer: Full invasiveness is not from the inside.
    Sabe H; Hashimoto S; Morishige M; Hashimoto A; Ogawa E
    Cell Adh Migr; 2008; 2(2):71-3. PubMed ID: 19262097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion.
    Morishige M; Hashimoto S; Ogawa E; Toda Y; Kotani H; Hirose M; Wei S; Hashimoto A; Yamada A; Yano H; Mazaki Y; Kodama H; Nio Y; Manabe T; Wada H; Kobayashi H; Sabe H
    Nat Cell Biol; 2008 Jan; 10(1):85-92. PubMed ID: 18084281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GEP100-Arf6-AMAP1-cortactin pathway frequently used in cancer invasion is activated by VEGFR2 to promote angiogenesis.
    Hashimoto A; Hashimoto S; Ando R; Noda K; Ogawa E; Kotani H; Hirose M; Menju T; Morishige M; Manabe T; Toda Y; Ishida S; Sabe H
    PLoS One; 2011; 6(8):e23359. PubMed ID: 21858086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rab5c promotes AMAP1-PRKD2 complex formation to enhance β1 integrin recycling in EGF-induced cancer invasion.
    Onodera Y; Nam JM; Hashimoto A; Norman JC; Shirato H; Hashimoto S; Sabe H
    J Cell Biol; 2012 Jun; 197(7):983-96. PubMed ID: 22734003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GEP100 regulates epidermal growth factor-induced MDA-MB-231 breast cancer cell invasion through the activation of Arf6/ERK/uPAR signaling pathway.
    Hu Z; Xu R; Liu J; Zhang Y; Du J; Li W; Zhang W; Li Y; Zhu Y; Gu L
    Exp Cell Res; 2013 Aug; 319(13):1932-1941. PubMed ID: 23747719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High level expression of AMAP1 protein correlates with poor prognosis and survival after surgery of head and neck squamous cell carcinoma patients.
    Sato H; Hatanaka KC; Hatanaka Y; Hatakeyama H; Hashimoto A; Matsuno Y; Fukuda S; Sabe H
    Cell Commun Signal; 2014 Mar; 12():17. PubMed ID: 24621372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor-GEP100-Arf6 axis affects the prognosis of lung adenocarcinoma.
    Oka S; Uramoto H; Shimokawa H; Yamada S; Tanaka F
    Oncology; 2014; 86(5-6):263-70. PubMed ID: 24902879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The guanine nucleotide exchange protein for ADP-ribosylation factor 6, ARF-GEP100/BRAG2, regulates phagocytosis of monocytic phagocytes in an ARF6-dependent process.
    Someya A; Moss J; Nagaoka I
    J Biol Chem; 2010 Oct; 285(40):30698-707. PubMed ID: 20601426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of epithelial-mesenchymal transition by cetuximab via the EGFR-GEP100-Arf6-AMAP1 pathway in head and neck cancer.
    Matsumoto Y; Sakurai H; Kogashiwa Y; Kimura T; Matsumoto Y; Shionome T; Asano M; Saito K; Kohno N
    Head Neck; 2017 Mar; 39(3):476-485. PubMed ID: 27880014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphatidylinositol-4-phosphate 5-kinase and GEP100/Brag2 protein mediate antiangiogenic signaling by semaphorin 3E-plexin-D1 through Arf6 protein.
    Sakurai A; Jian X; Lee CJ; Manavski Y; Chavakis E; Donaldson J; Randazzo PA; Gutkind JS
    J Biol Chem; 2011 Sep; 286(39):34335-45. PubMed ID: 21795701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The adaptor proteins p66Shc and Grb2 regulate the activation of the GTPases ARF1 and ARF6 in invasive breast cancer cells.
    Haines E; Saucier C; Claing A
    J Biol Chem; 2014 Feb; 289(9):5687-703. PubMed ID: 24407288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer.
    Hashimoto A; Handa H; Hata S; Tsutaho A; Yoshida T; Hirano S; Hashimoto S; Sabe H
    Cell Commun Signal; 2021 May; 19(1):54. PubMed ID: 34001163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Getting invasive with GEP100 and Arf6.
    Valderrama F; Ridley AJ
    Nat Cell Biol; 2008 Jan; 10(1):16-8. PubMed ID: 18172429
    [No Abstract]   [Full Text] [Related]  

  • 16. High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer.
    Tsutaho A; Hashimoto A; Hashimoto S; Hata S; Kachi S; Hirano S; Sabe H
    Cell Commun Signal; 2020 Jun; 18(1):101. PubMed ID: 32580737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/proline interface for prevention of breast cancer invasion and metastasis.
    Hashimoto S; Hirose M; Hashimoto A; Morishige M; Yamada A; Hosaka H; Akagi K; Ogawa E; Oneyama C; Agatsuma T; Okada M; Kobayashi H; Wada H; Nakano H; Ikegami T; Nakagawa A; Sabe H
    Proc Natl Acad Sci U S A; 2006 May; 103(18):7036-41. PubMed ID: 16636290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GEP100/Arf6 is required for epidermal growth factor-induced ERK/Rac1 signaling and cell migration in human hepatoma HepG2 cells.
    Hu Z; Du J; Yang L; Zhu Y; Yang Y; Zheng D; Someya A; Gu L; Lu X
    PLoS One; 2012; 7(6):e38777. PubMed ID: 22701712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ARF6 and AMAP1 are major targets of
    Hashimoto S; Furukawa S; Hashimoto A; Tsutaho A; Fukao A; Sakamura Y; Parajuli G; Onodera Y; Otsuka Y; Handa H; Oikawa T; Hata S; Nishikawa Y; Mizukami Y; Kodama Y; Murakami M; Fujiwara T; Hirano S; Sabe H
    Proc Natl Acad Sci U S A; 2019 Aug; 116(35):17450-17459. PubMed ID: 31399545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer.
    Hashimoto S; Mikami S; Sugino H; Yoshikawa A; Hashimoto A; Onodera Y; Furukawa S; Handa H; Oikawa T; Okada Y; Oya M; Sabe H
    Nat Commun; 2016 Feb; 7():10656. PubMed ID: 26854204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.